Navigation Links
Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
Date:9/28/2010

BONITA SPRINGS, Fla., Sept. 28 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, is pleased to announce the appointment of Mr. Neil Flanzraich as Executive Chairman of the Board of Directors.

"The appointment of Mr. Flanzraich is a very important milestone for Tigris Pharmaceuticals' future," said Edmundo Muniz, MD, PhD, President and CEO of Tigris, adding, "Neil brings to Tigris extraordinary ability and pharmaceutical industry experience and a remarkable track record of success. We are extremely pleased to welcome him to our company."

Mr. Flanzraich also serves as Chairman of ParinGenix, Inc., another privately owned biotechnology company.  He is also the founder and a principal of a venture capital firm, Leviathan Biopharma Group, LLC.  

For over seven years, prior to its sale in 2006, Mr. Flanzraich served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company acquired by TEVA Pharmaceutical Industries, Ltd. Prior to his tenure at IVAX, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm, and for thirteen years, he worked at Syntex Corporation, an international pharmaceutical company, where he was Senior Vice President and member of the Corporate Operating Committee.

"I am delighted to become Tigris Pharmaceuticals' Executive Chairman," said Mr. Flanzraich.  "I am joining a leadership team with deep expertise and an impressive record of accomplishment.  Our combined capabilities, shared values and focus and the company's exciting pipeline will make Tigris an extraordinarily successful enterprise."

Mr. Flanzraich serves as a director of Equity One, Inc., a real estate company, Continucare Corporation, a mixed model provider of primary care physician services, Chipotle Mexican Grill, a developer and operator of fast-casual, fresh Mexican food restaurants in the United States, and Canada, and England and Bellus Health, a biotechnology company focused on neurology products.  He also serves as a director of privately owned, Outcomes Health Information Solutions, LLC, a provider of healthcare data retrieval, analytic and management services.

Mr. Flanzraich graduated from Harvard College (magna cum laude, Phi Beta Kappa) and from Harvard Law School (magna cum laude).  

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology and other human diseases.  Tigris is currently initiating a Phase II trial for AFP-464, a novel anticancer agent in patients with breast cancer and is also conducting a multi-center Phase I dose escalation study for GGTI-2418, another first-in-class agent, at Abramson Cancer Center at The University of Pennsylvania and Indiana University Melvin and Bren Simon Cancer Center.  

With a management team that has a proven track record in guiding molecules from the early stages of clinical development to successful worldwide approvals, we offer large pharmaceutical drug development expertise in conjunction with the agility and speed of a small organization.Contact:  For Tigris PharmaceuticalsElaine FloydTigris Pharmaceuticals, Inc.(239) 444-5400info@tigrispharma.comThis news release contains forward-looking statements.  Such statements are valid only as of today, and Tigris disclaims any obligation to update this information.  These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on the company's current beliefs and expectations as to such future outcomes.  Drug development involves a high degree of risk.  Factors that might cause such a material difference include, among others uncertainties related to Tigris' ability to attract and retain partners for its technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, its pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates from other pharmaceutical companies, product pricing and third party reimbursement.


'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
2. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
3. Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
6. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
7. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
8. Lotus Pharmaceuticals Announces Two Senior Management Appointments
9. NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa
10. Endo Pharmaceuticals Receives FDA Priority Review for New Formulation of Long-Acting Oxymorphone Designed to be Crush Resistant
11. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... Come to PAINWeekEnd ... 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , An ... staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... , ... “Reflections of God’s Work”: an enlightening collection of life lessons leading ... of published author, Jerri Broglin, a survivor of great loss who gained insight on ... eye-opener for those searching for answers, as we are finding the answers that are ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Life of ... University of Florida. The event will be held at 7:30 pm on May 10th ... Block and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community ...
Breaking Medicine News(10 mins):